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Abstract
© 2018 Bulatov, Zagidullin, Valiullina, Sayarova and Rizvanov. Ubiquitin-proteasome system
(UPS) is a primary signaling pathway for regulation of intracellular protein levels. E3 ubiquitin
ligases, substrate-specific members of the UPS, represent highly attractive protein targets for
drug  discovery.  The  importance  of  E3  ligases  as  prospective  targets  for  small  molecule
modulation is reinforced by ever growing evidence of their role in cancer and other diseases. To
date the number of potent compounds targeting E3 ligases remains rather low and their rational
design constitutes a challenging task. To successfully address this problem one must take into
consideration the multi-subunit  nature of  many E3 ligases that  implies  multiple  druggable
pockets and protein-protein interfaces. In this review, we briefly cover the current state of drug
discovery in the field of RING-type E3 ligases with focus on MDM and Cullin families as targets.
We also provide an overview of small molecule chimeras that induce RING-type E3-mediated
proteasomal degradation of substrate proteins of interest.
http://dx.doi.org/10.3389/fphar.2018.00450
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